Clinical trials: Immunomodulation
Acute Brain Injury, Transcutaneous Vagus Nerve Stimulation
The Role of Transcutaneous Vagus Nerve Stimulation in Treatment of Acute Brain Injury
Acute brain injury is a major global health problem associated with high mortality and morbidity, limited therapeutic options, prolonged hospital stays, and long-term disability that significantly impairs quality of life and…
- Conditions
- Acute Brain Injury, Transcutaneous Vagus Nerve Stimulation, Neuromodulation, Immunomodulation
- Trial name
- NCT07384845
- Testing
- transcutaneous vagus nerve stimulation (tVNS)
- Where
- Croatia
- Volunteers
- 60 people
- Sponsor
- Clinical Hospital Centre Zagreb
Brittle Type 1 Diabetes Mellitus
Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
- Trial name
- NCT05480657
- Testing
- AT-1501 IV Infusion, Isolated cadaveric islet cells
- Where
- United States
- Sponsor
- Eledon Pharmaceuticals
Human Immunodeficiency Virus
Effect of High Dose Vitamin D Supplementation on HIV Latency
HIV persists despite antiretroviral therapy (ART) and is associated with chronic inflammation. This inflammation is thought to prevent an effective immune response against the virus and is mediated at least in part by gut…
- Trial name
- VIVA (NCT03426592)
- Testing
- Vitamin D3, 10000 Intl Units Oral Capsule
- Where
- 4 sites in Australia
- Volunteers
- 30 people
- Sponsor
- University of Melbourne
Papilloma Viral Infection, CIN1
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
HPV infection can lead to cancer, especially when precancerous lesions have developed and high-risk HPV is present. Glizigen is an oral and intravaginal treatment based on activated glycyrrhizinic acid that has shown potential…
- Conditions
- Papilloma Viral Infection, CIN1, LSIL, Low Grade Squamous Intraepithelial Lesion
- Trial name
- NCT05916911
- Testing
- Glizigen
- Where
- 4 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Catalysis SL
Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Background: The chemotherapy combination DA-EPOCH-RP includes the drugs etoposide (E), prednisone (P), vincristine (O), cyclophosphamide (C), doxorubicin (H), rituximab (R), and pomalidomide (P).
- Trial name
- NCT02228512
- Testing
- Pomalidomide, Rituximab, Prednisone
- Sponsor
- National Cancer Institute (NCI)
Hymenoptera Venom Allergy
Virtual-reality Induced Immune Modulation in Allergic Patients
This study investigates whether immersive virtual reality (VR) exposure to allergen-related stimuli can modulate behavioural, neurophysiological, psychophysiological, and immune responses in adults with bee or wasp venom allergy.
- Trial name
- NCT07721233
- Testing
- Allergen-related immersive virtual reality exposure, Control immersive virtual reality exposure
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Geneva, Switzerland
Colon Cancer
A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer
The central hypothesis for this study is that it is safe and feasible to administer intraluminal photodynamic therapy (PDT) to colon cancers by colonoscopy to induce localized inflammatory/immune response.
- Trial name
- NCT01522677
- Testing
- PDT with 5-ALA radiosensitization
- Where
- 2 sites in United States
- Sponsor
- Edward Nelson
Type 1 Diabetes
Stem Cell Educator Therapy in Type 1 Diabetes
The translational potential to the clinical applications of cord blood stem cells has increased enormously in recent years, mainly because of its unique advantages including no risk to the donor, no ethical issues, low risk of…
- Trial name
- NCT01350219
- Testing
- Stem Cell Educator
- Where
- 4 sites in China, Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Throne Biotechnologies Inc.
Immune Surveillance
Acute Immune Modulation by Probiotic Strain
Clinical proof-of-concept study, comparing the acute immune impacts of 3 doses of a probiotic strain to a placebo. This study involves twenty-four participants, composed of healthy adults, who will be taking a placebo and 3…
- Trial name
- NCT06754228
- Testing
- Probiotic Agent
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Natural Immune Systems Inc
Type 1 Diabetes
Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy
The purpose of this study is to determine whether dendritic cells collected via leukapheresis and incubated with antisense DNA oligonucleotides and then injected back into the same subject will serve as modulators of the immune…
- Trial name
- NCT02354911
- Testing
- Immunoregulatory Dendritic Cells
- Sponsor
- DiaVacs, Inc.
Type 1 Diabetes
Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®
This is an extension study to evaluate the safety and tolerability of long-term treatment with DiaPep277® and to determine the long-term treatment effect of DiaPep277® on parameters of metabolic control and on preservation of…
- Trial name
- DIA-AID 2 (NCT01898286)
- Testing
- DiaPep277®
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Andromeda Biotech Ltd.
Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II
Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma
This study is for adult females who have been newly diagnosed with breast cancer that includes surgery as part of standard cancer treatment.
- Trial name
- NCT01816555
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Medical University of South Carolina
Septic Shock
Activated Protein C and Corticosteroids for Human Septic Shock
This study aims at comparing the efficacy and safety of recombinant human activated protein C to that of low dose of corticosteroids and at investigating the interaction between these drugs in the management of septic shock
- Trial name
- APROCCHS (NCT00625209)
- Testing
- recombinant human activated protein C and hydrocortisone and fludrocortisone
- Where
- 4 sites in France
- Volunteers
- 1,241 people
- Sponsor
- University of Versailles
Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain.
- Conditions
- Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme
- Trial name
- NCT05864534
- Testing
- Balstilimab, Botensilimab, Liposomal Doxorubicin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Covid19
IMUNOR® Preparation in the Prevention of COVID-19
The aim of the study is to achieve prevention of COVID-19 disease in healthcare professionals with the administration of the IMUNOR® preparation, and decreasing the symptoms should the disease appear.
- Trial name
- NCT04710381
- Testing
- IMUNOR
- Where
- Czechia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University Hospital Ostrava
Triple Negative Breast Cancer
Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers
Summary Points: 1. High Risk Breast Cancers: Triple negative cancer is considered high risk due to high rate of local and systemic failure.
- Trial name
- LOGIC (NCT05806385)
- Testing
- Cryoablation, Cryoablation combined with PD1 Inhibitor
- Volunteers
- 36 people
- Sponsor
- Texas Tech University Health Sciences Center
Malignant Glioma of Brain, Astrocytoma
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the…
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma
- Trial name
- rQNestin (NCT03152318)
- Testing
- rQNestin, Cyclophosphamide, Stereotactic biopsy
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Atopic Dermatitis
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
Clinical data suggest that treatment with OM-85, by inducing an early contact with bacterial extracts, could modulate the immunity of children with Atopic Dermatitis, and thus play an active role in the treatment of Atopic…
- Trial name
- NCT05222516
- Testing
- Broncho-Vaxom
- Where
- 28 sites in France, Germany and 2 more
- Volunteers
- 63 people
- Sponsor
- OM Pharma SA
Malignant Neoplasms, Tuberculosis (TB)
Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases
This interventional study evaluated the efficacy of Naderin (sodium nucleinate) for the prophylaxis of complications during basic therapy and medical rehabilitation in patients with socially significant diseases, including…
- Conditions
- Malignant Neoplasms, Tuberculosis (TB), HEPATITIS C (HCV)
- Trial name
- NADERIN-SSD (NCT07671508)
- Testing
- Naderin, Standard Therapy
- Volunteers
- 75 people
- Sponsor
- MIPO Clinic
Inflammation
Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases
The aim of the study is to investigate in vitro the impact of a novel anti-inflammatory treatment on costimulatory molecules expressed on monocytes.
- Trial name
- Super-Bio (NCT02839278)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon